Sequence variants in toll-like receptor gene cluster (TLR6-TLR1-TLR10) and prostate cancer risk

Journal of the National Cancer Institute

Volumn 97, Issue 7, 2005, Pages 525-532

  Sun, Jielin ^a   Wiklund, Fredrik ^b   Zheng, S Lilly ^a   Chang, Baoli ^a   Bälter, Katarina ^c   Li, Liwu ^a   Johansson, Jan Erik ^d,f   Li, Ge ^a   Adami, Hans Olov ^c   Liu, Wennuan ^a   Tolin, Amy ^a   Turner, Aubrey R ^a   Meyers, Deborah A ^a   Isaacs, William B ^e   Xu, Jianfeng ^a   Grönberg, Henrik ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b UMEÅ UNIVERSITY   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 10; TOLL LIKE RECEPTOR 6; CELL SURFACE RECEPTOR; MEMBRANE PROTEIN; TLR4 PROTEIN, HUMAN; TLR6 PROTEIN, HUMAN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 4;

ADULT; AGED; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CHROMOSOME 4P; CLADISTICS; CONFIDENCE INTERVAL; CONTROLLED STUDY; GENE CLUSTER; GENE FREQUENCY; GENE FUNCTION; GENE IDENTIFICATION; GENE LOCATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HETEROZYGOTE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MOLECULAR EVOLUTION; PHYLOGENETIC TREE; POPULATION RESEARCH; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE; WILD TYPE; FOUNDER EFFECT; GENETIC PREDISPOSITION; GENETICS; PROSTATE TUMOR; RISK; STATISTICAL MODEL; SWEDEN;

CASE-CONTROL STUDIES; FOUNDER EFFECT; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; LOGISTIC MODELS; MALE; MEMBRANE GLYCOPROTEINS; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; RECEPTORS, CELL SURFACE; SWEDEN; TOLL-LIKE RECEPTOR 1; TOLL-LIKE RECEPTOR 10; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTOR 6; TOLL-LIKE RECEPTORS; VARIATION (GENETICS);

EID: 15944377845     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/dji070     Document Type: Article

References (37)

1. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003;349:366-81.
2. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, et al. Environmental and heritable factors in the causation of cancer - analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000;343:78-85.
3. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539-45.
4. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7.
5. Nelson WG, DeWeese TL, DeMarzo AM. The diet, prostate inflammation, and the development of prostate cancer. Cancer Metastasis Rev 2002;21:3-16.
6. De Marzo AM, Marchi VL, Epstein JI, Nelson WG. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol 1999;155:1985-92.
7. Shah R, Mucci NR, Amin A, Macoska JA, Rubin MA. Postatrophic hyperplasia of the prostate gland: neoplastic precursor or innocent bystander? Am J Pathol 2001;158:1767-73.
8. Carpten J, Nupponen N, Isaacs S, Sood R, Robbins C, Xu J, et al. Germ-line mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet 2002;30:181-4.
9. Xu J, Zheng SL, Komiya A, Mychaleckyj JC, Isaacs SD, Hu JJ, et al. Germ-line mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet 2002;32:321-5.
10. Zheng SL, Augustsson-Balter K, Chang B, Hedelin M, Li L, Adami HO, et al. Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: results from the CAncer Prostate in Sweden Study. Cancer Res 2004;64:2918-22.
11. Singh BP, Chauhan RS, Singhal LK. Toll-like receptors and their role in innate immunity. Curr Sci 2003;85:1156-64.
12. Barton GM, Medzhitov R. Toll-like receptors and their ligands. Curr Top Microbiol Immunol 2002;270:81-92.
13. Chuang T, Ulevitch RJ. Identification of hTLR10: a novel human Toll-like receptor preferentially expressed in immune cells. Biochim Biophys Acta 2001;1518:157-61.
14. Yamamoto M, Takeda K, Akira S. TIR domain-containing adaptors define the specificity of TLR signaling. Mol Immunol 2004;40:861-8.
15. Takeuchi O, Kawai T, Muhlradt PF, Morr M, Radolf JD, Zychlinsky A, et al. Discrimination of bacterial lipoproteins by Toll-like receptor 6. Int Immunol 2001;13:933-40.
16. Takeuchi O, Sato S, Horiuchi T, Hoshino K, Takeda K, Dong Z, et al. Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins. J Immunol 2002;169:10-4.
17. Ozinsky A, Underhill DM, Fontenot JD, Hajjar AM, Smith KD, Wilson CB, et al. The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors. Proc Natl Acad Sci U S A 2000;97:13766-71.
18. Hajjar AM, O'Mahony DS, Ozinsky A, Underhill DM, Aderem A, Klebanoff SJ, et al. Cutting edge: functional interactions between toll like receptor (TLR) 2 and TLR1 or TLR6 in response to phenol-soluble modulin. J Immunol 2001;166:15-9.
19. Janssens S, Beyaert R. Role of Toll-like receptors in pathogen recognition. Clin Microbiol Rev 2003;16:637-46.
20. Spitzer JH, Visintin A, Mazzoni A, Kennedy MN, Segal DM. Toll-like receptor 1 inhibits Toll-like receptor 4 signaling in endothelial cells. Eur J Immunol 2002;32:1182-7.
21. Schroder FH, Hermanek P, Denis L, Fair WR, Gospodarowicz MK, Pavone-Macalus M. The TNM classification of prostate cancer. Prostate Suppl 1992;4:129-38.
22. Stephens M, Smith NJ, Donnelly P. A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001;68:978-89.
23. Kumar S, Tamura K, Nei M. MEGA: molecular evolutionary genetics analysis software for microcomputers. Bioinformatics 1994;10:189-91.
24. Saitou N, Nei M. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol 1987;4:406-25.
25. Rzhetsky A, Nei M. Theoretical foundation of the minimum-evolution method of phylogenetics inference. Mol Biol Evol 1993;10:1073-95.
26. Nei M, Kumar S. Molecular evolution and phylogenetics. New York (NY): Oxford University Press; 2000.
27. Falsenstein J. Confidence limits on phylogenies: an approach using the bootstrap. Evolution 1985;39:783-91.
28. Fitch WM. Towards defining the course of evolution: minimum change for a specific tree topology. Syst Zool 1971;20:406-16.
29. Weir BS. Genetic analysis II: methods for discrete population genetic data. Sunderland (MA): Sinauer; 1996.
30. Lilienfeld AM, Lifienfeld DE. Foundations of epidemiology. 2nd ed. New York (NY): Oxford University Press; 1980.
31. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002;70:425-34.
32. Platz EA, De Marzo AM. Epidemiology of inflammation and prostate cancer. J Urol 2004;171:S36-S40.
33. Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 2004;96:434-42.
34. Pahl HL, Scheibe RJ, Zhang DE, Chen HM, Galson DL, Maki RA, et al. The proto-oncogene PU.1 regulates expression of the myeloid-specific CD11b promoter. J Biol Chem 1993;268:5014-20.
35. Klemsz MJ, McKercher SR, Celada A, Van Beveren C, Maki RA. The macrophage and B cell-specific transcription factor PU.1 is related to the ets oncogene. Cell 1990;61:113-24.
36. Ng PC, Henikoff S. SIFT: predicting amino acid changes that affect protein function. Nucleic Acids Res 2003;31:3812-4.
37. Sunyaev S, Ramensky V, Koch I, Lathe W, III, Kondrashov AS, Bork P. Prediction of deleterious human alleles. Hum Mol Genet 2001;10:591-7.